Rituximab Versus Mycophenolate in the Treatment of Recalcitrant Connective Tissue Disease-Associated Interstitial Lung Disease.
Lisa ZhuMelody P ChungLaurence GagneHaiwei Henry GuoZachary GuentherShufeng LiSusan JacobsJulie MorissetJoshua J MooneyRishi RajLorinda S ChungPublished in: ACR open rheumatology (2020)
Rituximab ± MMF did not significantly change pulmonary function compared with MMF alone, but it did result in a relative decrease in average daily prednisone dose in a population with recalcitrant CTD-ILD.